- Home
- AUST vs NRSN Comparison
AUST vs NRSN Comparison
Compare AUST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- NRSN
- Stock Information
- Founded
- AUST 2020
- NRSN 2017
- Country
- AUST Canada
- NRSN Israel
- Employees
- AUST N/A
- NRSN N/A
- Industry
- AUST
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- NRSN Health Care
- Exchange
- AUST Nasdaq
- NRSN Nasdaq
- Market Cap
- AUST 19.7M
- NRSN 17.8M
- IPO Year
- AUST 2022
- NRSN 2021
- Fundamental
- Price
- AUST $1.23
- NRSN $1.36
- Analyst Decision
- AUST
- NRSN Hold
- Analyst Count
- AUST 0
- NRSN 1
- Target Price
- AUST N/A
- NRSN N/A
- AVG Volume (30 Days)
- AUST 131.6K
- NRSN 456.2K
- Earning Date
- AUST 11-06-2024
- NRSN 12-31-2024
- Dividend Yield
- AUST N/A
- NRSN N/A
- EPS Growth
- AUST N/A
- NRSN N/A
- EPS
- AUST N/A
- NRSN N/A
- Revenue
- AUST N/A
- NRSN N/A
- Revenue This Year
- AUST N/A
- NRSN N/A
- Revenue Next Year
- AUST N/A
- NRSN N/A
- P/E Ratio
- AUST N/A
- NRSN N/A
- Revenue Growth
- AUST N/A
- NRSN N/A
- 52 Week Low
- AUST $0.62
- NRSN $0.51
- 52 Week High
- AUST $3.19
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- AUST 34.71
- NRSN 67.35
- Support Level
- AUST $1.12
- NRSN $0.80
- Resistance Level
- AUST $1.82
- NRSN $1.29
- Average True Range (ATR)
- AUST 0.18
- NRSN 0.14
- MACD
- AUST -0.05
- NRSN 0.05
- Stochastic Oscillator
- AUST 12.76
- NRSN 90.16
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.